Medexus Pharmaceuticals Inc (P731) Stock Statistics & Valuation Metrics

Medexus Pharmaceuticals Inc has a market cap or net worth of EUR 102.72M. The enterprise value is EUR 192.00M.

Market Cap

EUR 102.72M

Enterprise Value

EUR 192.00M

Medexus Pharmaceuticals Inc has 31,425,983 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

31,425,983

Owned by Insiders

8.12%

Owned by Institutions

2.36%

Medexus Pharmaceuticals Inc’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is 6.08%.

Return on Equity (ROE)

-0.05

Return on Assets (ROA)

-0.02

Return on Invested Capital (ROIC)

6.08%

Return on Capital Employed (ROCE)

0.06

Revenue Per Employee

1.10M

Profits Per Employee

-26.60K

Employee Count

90

Asset Turnover

0.67

Inventory Turnover

1.35

The current PE Ratio of Medexus Pharmaceuticals Inc is -47.85. Medexus Pharmaceuticals Inc’s PEG ratio is -0.58.

PE Ratio

-47.85

PS Ratio

1.11

PB Ratio

2.42

Price to FCF

-94.67

Price to Operating Cash Flow

8.40

PEG Ratio

-0.58

In the last 12 months, Medexus Pharmaceuticals Inc had revenue of 99.33M and earned -2.39M in profits. Earnings per share was -0.07.

Revenue

99.33M

Gross Profit

54.41M

Operating Income

5.83M

Pretax Income

-2.27M

Net Income

-2.39M

EBITDA

12.66M

Earnings Per Share (EPS)

-0.07

In the last 12 months, operating cash flow was 13.84M and capital expenditures -15.05M, giving a free cash flow of -1.21M billion.

Operating Cash Flow

13.84M

Free Cash Flow

-1.21M

Free Cash Flow per Share

-0.04

Medexus Pharmaceuticals Inc pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-1.06%

Earnings Yield

-2.04%

Beta

0.96

52-Week Price Change

102.64%

50-Day Moving Average

3.06

200-Day Moving Average

2.58

Relative Strength Index (RSI)

50.00

Average Volume (3m)

834

Medexus Pharmaceuticals Inc upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).

Last Earnings Date

Nov 11, 2026

Next Earnings Date

Nov 11, 2026

Ex-Dividend Date

―

Medexus Pharmaceuticals Inc as a current ratio of 1.19, with Debt / Equity ratio of 45.45%

Current Ratio

1.19

Quick Ratio

0.57

Debt to Market Cap

0.22

Net Debt to EBITDA

1.24

Interest Coverage Ratio

1.12

In the past 12 months, Medexus Pharmaceuticals Inc has paid 120.00K in taxes.

Income Tax

120.00K

Effective Tax Rate

-0.05

Medexus Pharmaceuticals Inc EV to EBITDA ratio is 10.69, with an EV/FCF ratio of -111.57.

EV to Sales

1.31

EV to EBITDA

10.69

EV to Free Cash Flow

-111.57

EV to Operating Cash Flow

9.77

Medexus Pharmaceuticals Inc has EUR 5.34M in cash and marketable securities with EUR 26.21M in debt, giving a net cash position of -EUR 20.88M billion.

Cash & Marketable Securities

EUR 5.34M

Total Debt

EUR 26.21M

Net Cash

-EUR 20.88M

Net Cash Per Share

-EUR 0.66

Tangible Book Value Per Share

-EUR 0.75

Gross margin is 54.73%, with operating margin of 6.69%, and net profit margin of -2.29%.

Gross Margin

54.73%

Operating Margin

6.69%

Pretax Margin

-2.29%

Net Profit Margin

-2.29%

EBITDA Margin

12.24%

EBIT Margin

2.83%

The average price target for Medexus Pharmaceuticals Inc is EUR 4.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

EUR 4.13

Price Target Upside

28.25% Upside

Analyst Consensus

Moderate Buy

Analyst Count

1

Revenue Growth Forecast

-8.95%

EPS Growth Forecast

-332.96%

Smart Score

7

AI Score

―